Abstracts tagged "Biologic drugs"

Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
Abstract Number: 1164 • 2014 ACR/ARHP Annual Meeting
Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway)
Polina Putrik¹, Sofia Ramiro², Elisabeth Lie³, Andras Keszei⁴, Desirée van der Heijde⁵, Robert Landewé⁶, Tore K. Kvien⁷, Till Uhlig⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁷Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Biologic DMARDs (bDMARDs) have greatly improved the outcome of rheumatoid arthritis (RA). Investigating possible inequities in access to bDMARDs across socio-economic factors is important,…
Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting
Durability of First Biologic Is Not Influenced By Initial/Early DAS28
Gina Rohekar¹, Binu Jacob², Janet E. Pope³ and Claire Bombardier⁴, ¹Rheumatology, St. Joseph's Hospital, London, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³Medicine, Western University, London, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting. Patients are enrolled and prospectively followed to…
Abstract Number: 1144 • 2014 ACR/ARHP Annual Meeting
Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis
Nick Bansback¹, Diane V. Lacaille², Daphne Guh³, Kamran Shojania⁴ and Aslam H. Anis³, ¹School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada/University of British Columbia, Richmond, BC, Canada, ³St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Recent randomized controlled trials in rheumatoid arthritis (RA) patients have determined that a strategy of first adding the two Disease Modifying Anti-Rheumatic Drugs (DMARDs)…
Abstract Number: 2202 • 2014 ACR/ARHP Annual Meeting
Pilot Study of Tocilizumab in Patients with Erdheim-Chester Disease
Giulio Cavalli¹, Alvise Berti¹, Barbara Gulgielmi¹, Marco Gelpi², Riccardo Biavasco², Corrado Campochiaro¹, Alessandro Tomelleri², Marina Ferrarini³, Maria Grazia Sabbadini² and Lorenzo Dagna², ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Vita-Salute San Raffaele University, Milan, Italy, ³Department of Oncology, San Raffaele Scientific Institute, MIlan, Italy
Background/Purpose Erdheim-Chester disease (ECD) is a rare, systemic disorder of unknown etiology, characterized by tissue infiltration with CD68+, CD1a- foamy histiocytes. ECD is a chronic,…
Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…
Abstract Number: 2133 • 2014 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT
Koichi Okamura¹, Yukio Yonemoto¹, Chisa Okura² and Kenji Takagishi¹, ¹Orthopaedic Surgery, Gunma University, Maebashi, Japan, ²Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose: A humanized anti-interleukin-6 receptor (anti-IL-6R) antibody, tocilizumab (TCZ), is one of the biologics and the C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR)…
Abstract Number: 944 • 2014 ACR/ARHP Annual Meeting
Predict the Chance of Remission for Your RA Patient in Real Life
Till Uhlig¹, Vibeke Norvang², Elisabeth Lie¹, Erik Rødevand³, Knut Mikkelsen⁴, Åse S. Lexberg⁵, Synøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁴Revmatismesykehuset, Lillehammer, Norway, ⁵Dept. of Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁶Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission (REM) is the treatment target in rheumatoid arthritis (RA), and there are several composite REM criteria available. Knowledge on how disease duration affects REM…
Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Chris Tonner¹, Gabriela Schmajuk² and Jinoos Yazdany², ¹3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…
Abstract Number: 483 • 2014 ACR/ARHP Annual Meeting
Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience
Francesca De Nard¹, Vittorio Grosso², Monica Todoerti³, Carlomaurizio Montecucco⁴ and Roberto Caporali⁵, ¹Division of Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Division of Rheumatology, University of Pavia, Foundation IRCCS Policlinico S. Matteo, Pavia, Italy, ³Rheumatology, University of Pavia, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁴Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ⁵Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose HBV infection represents a major issue in patients with rheumatoid arthritis (RA) undergoing biological disease-modifying anti-rheumatic drugs (bDMARDs) (1). While the risk of hepatitis…
Abstract Number: 2040 • 2014 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients Treated with Biologic Drug Therapy
Laura Encinas¹, Maria Haye Salinas¹, Veronica Saurit¹, Alejandro J. Alvarellos², Francisco Caeiro¹, Cristina Battagliotti³, Ida Elena Exeni⁴, Carla Gobbi⁵, Bernardo Pons-Estel⁶, Ingrid Strusberg⁷, Sergio Paira⁸, Eduardo Mussano⁹, Maria Apaz¹⁰, Ana Quinteros¹¹, Ana Capuccio¹², Mercedes De La Sota¹³, Maria Larroude¹⁴, Amelia Granel¹⁵, Oscar Rillo¹⁶, Enrique Soriano¹⁷, Gustavo Citera¹⁸, Diana Dubinsky¹⁹, Mari Delgado²⁰, Analia Alvarez²¹, Graciela Gómez²², Gustavo Casado²³, Santiago Aguero²⁴, Monica Sacnum²⁰, Mercedes Garcia²⁰, Sidney Soares de Souza²⁵, Edson Javier Velozo²⁶, C Paruolo²⁰, Monica Patricia Diaz²⁷, Emilia Cavillion²⁸, Juan C. Barreira²⁹, Gimena Gómez³⁰ and E. Scheines³¹, ¹Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ²Reumatología, Hospital Privado Córdoba, Córdoba, Argentina, ³Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, ⁴Sanatorio Parque, Cordoba, Argentina, ⁵Hospital Còrdoba, Còrdoba, Argentina, ⁶Sanatorio Parque, Rosario, Argentina, ⁷Instituto Reumatológico Strusberg, Cordoba, Argentina, ⁸Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁹Hospital Nacional De Clinicas, Mariquita Sanchez 2304, Buenos Aires, Argentina, ¹⁰Pediatric Rheumatology, Hospital de niños de cordoba, córdoba, Argentina, Argentina, ¹¹Centro Integral de Reumatología, Tucumán, Argentina, ¹²Rheumatology, Hospital cesar Milstein, Buenos Aires, Argentina, ¹³Consultorio, Bahia Blanca, Argentina, ¹⁴Consultorio, Buenos Aires, Argentina, ¹⁵Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ¹⁶Rheumatology, Hospital Sirio Libanes, Buenos Aires, Argentina, ¹⁷Hospital Italiano, Buenos Aires, Argentina, ¹⁸Universidad de Buenos Aires, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital de Clinicas, Jose de San Martin, Capital Federal, Argentina, ²⁰consultorio, Buenos Aires, Argentina, ²¹Cemic, Buenos Aires, Argentina, ²²Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ²³Hospital Militar Central, Buenos Aires, Argentina, ²⁴Pasaje Sanchez Gardel 148, Sanatorio Pasteur, Catamarca, Argentina, ²⁵REUMAR, Buenos Aires, Argentina, ²⁶25 DE MAYO 255 -LIBERTADOR SAN, Sanatorio Adventista Del Plata, Entre Rios, Argentina, ²⁷Espana 327, consultorio, Bariloche, Argentina, ²⁸Consultorio, Cordoba, Argentina, ²⁹Rheumatology, British Hospital, Buenos Aires, Argentina, ³⁰Hospital Argerich, Buenos Aires, Argentina, ³¹Rheumatology, Hospital Manuel Rocca, Ciudad Autonoma de Buenos Aires, Argentina
Background/Purpose Biological drug therapy is frequently used to treat autoimmune diseases.These drugs have an increased risk of infections, among them opportunistic infections.To evaluate the frequency…
Abstract Number: 476 • 2014 ACR/ARHP Annual Meeting
Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Lucile Poiroux¹, Yannick Allanore², Andre Kahan³ and Jerome Avouac⁴, ¹Rhumatologie A, Cochin Hospital, Paris, France, ²Rheumatology, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, ³Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁴Cochin Hospital, Paris, France
Background/Purpose: TNF-a inhibitors have changed the prognosis of rheumatoid arthritis (RA). The number of molecules and the time of exposure have increased. However, few studies…
Abstract Number: 2036 • 2014 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with RA
Seoyoung C. Kim¹, Sebastian Schneeweiss², Jun Liu³, Elizabeth W. Karlson⁴, Jeffrey N. Katz⁵, Sarah Feldman² and Daniel H. Solomon⁶, ¹Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Human papillomaviruses (HPV) are causes of high-grade cervical dysplasia and cervical cancer. Persistent HPV infection, the major risk factor for cervical cancer, is associated…
Abstract Number: 473 • 2014 ACR/ARHP Annual Meeting
Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids
Jacques Morel¹, Florence Tubach^2,3, Yannick Allanore⁴, Daniel Wendling⁵, Celine Cozic⁶, Emmanuelle Dernis Labous⁷, Eric Legangneux⁸, Thao Pham⁹, Sophie Odoit¹⁰, Isabelle Roitg¹¹, Isabelle Koné-Paut¹², Pierre Quartier¹³, Jean Sibilia¹⁴ and Severine Guillaume Czitrom¹⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ³INSERM, Universite Paris Diderot, Paris, France, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁶Rheumatology, CHD la Roche sur Yon, La Roche Sur Yon, France, ⁷Rhumatologie, Ch Du Mans, Le Mans, France, ⁸Rheumatology, Centre Hospitalier Public du Cotentin, 50100, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Dermatology, CHU de la Réunion, Saint Denis, France, ¹¹Hopital De Perpignan, Perpignan, France, ¹²Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁵Ch De Bicetre, Le Kremlin Bicetre Cedex, France
Background/Purpose To assess varicella zona virus (VZV) infection features under biological drugs. Methods A call for observations was sent from april 2013 to april 2014…
Abstract Number: 2042 • 2014 ACR/ARHP Annual Meeting
Tuberculin Conversion in Patients with Autoimmune Arthropathies Receiving Biologic Therapy
Osvaldo Luis Cerda¹, Maria de los Angeles Correa², Amelia Granel³, Ana Inés Marcos³, Claudia L. Giraldo⁴, Oscar L. Rillo⁵ and Gustavo Citera⁶, ¹Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ⁴Rheumatology, Hospital Gral. de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁵Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: Patients receiving biologic DMARDs are at increase risk of developing tuberculosis (TB). Tuberculosis skin test (TST) is recommended to screen for TB infection prior…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].